Lexicon Pharmaceuticals, Inc.  

(Public, NASDAQ:LXRX)   Watch this stock  
Find more results for LXRX
15.74
+0.19 (1.22%)
Feb 17 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 15.46 - 16.05
52 week 8.37 - 19.62
Open 15.50
Vol / Avg. 745,880.00/644,081.00
Mkt cap 1.66B
P/E     -
Div/yield     -
EPS -0.30
Shares 104.04M
Beta 0.60
Inst. own 107%
Feb 27, 2017
Q4 2016 Lexicon Pharmaceuticals Inc Earnings Release (Estimated) - 9:30AM EST - Add to calendar
Dec 21, 2016
Lexicon Pharmaceuticals Inc to Discuss the inTandem2 Phase 3 Top-line Results Conference Call - Webcast
More events from DailyFinance »    

Key stats and ratios

Q3 (Sep '16) 2015
Net profit margin -129.94% -3.60%
Operating margin -126.03% 1.13%
EBITD margin - 4.45%
Return on average assets -26.87% -0.83%
Return on average equity -71.78% -1.64%
Employees 120 -
CDP Score - -

Address

8800 Technology Forest Pl
THE WOODLANDS, TX 77381-1160
United States - Map
+1-281-8633000 (Phone)
+1-281-8638088 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Lexicon Pharmaceuticals, Inc. (Lexicon) is a biopharmaceutical company. The Company focuses on the development of treatments for human disease. The Company is engaged in the development of two drug candidates: telotristat etiprate (LX1032) and sotagliflozin (LX4211). The Company's telotristat etiprate, is an orally delivered small molecule drug candidate, as a treatment for carcinoid syndrome. LX1032 inhibits tryptophan hydroxylase (TPH), which is an orally-delivered small molecule compound that the Company is developing for the treatment of carcinoid syndrome. Sotagliflozin, or LX4211, which is an orally-delivered small molecule compound that the Company is developing for the treatment of type 1 and type 2 diabetes mellitus. LX2761 is an orally-delivered small molecule compound for the treatment of diabetes. LX9211 is an orally-delivered small molecule compound for the treatment of neuropathic pain. The Company's other programs include LX1033, LX2931 and LX7101.

Officers and directors

Raymond Debbane Independent Chairman of the Board
Age: 61
Bio & Compensation  - Reuters
Lonnel Coats President, Chief Executive Officer, Director
Age: 52
Bio & Compensation  - Reuters
Jeffrey L. Wade J.D. Chief Financial Officer, Executive Vice President - Corporate and Administrative Affairs
Age: 51
Bio & Compensation  - Reuters
Pablo Lapuerta M.D. Executive Vice President, Chief Medical Officer
Age: 52
Bio & Compensation  - Reuters
Alan J. Main Ph.D. Executive Vice President - CMC and Supply Operations
Age: 62
Bio & Compensation  - Reuters
Praveen Tyle Ph.D. Executive Vice President of Research and Development
Age: 56
Bio & Compensation  - Reuters
James F. Tessmer Vice President - Finance & Accounting
Age: 56
Bio & Compensation  - Reuters
Gary Branch Vice President - Sales
Bio & Compensation  - Reuters
Kiernan Seth Ph.D. Vice President - Marketing
Bio & Compensation  - Reuters
Alexander A Santini Chief Commercial Officer
Bio & Compensation  - Reuters